Bottle Label (10544 185 30 16714 661 02)
Gabapentin
Product Images NDC 10544-185
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 10544-185). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (Gabapentin Fig1)
Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (Gabapentin Fig2)
This is a report on a study that evaluates the effect of Gabapentin on pain relief over a period of 7 weeks. The study has a 3-week dose titration period followed by a 4-week fixed dose period. The table shows the mean pain score at baseline and weekly intervals with three treatment options: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The statistical analysis suggests that the pain reduction effect of Gabapentin is significant (p<0.001).*
Figure 3. Proportion Of Responders (patients With ≥50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (Gabapentin Fig3)
Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study (Gabapentin Fig4)
Chemical Structure (Gabapentin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
